| 腔内灌注贝伐单抗治疗恶性胸腹腔积液的研究进展 |
| |
| 引用本文： | 刁彦文,董 召,曲秀娟,刘云鹏,曲晶磊. 腔内灌注贝伐单抗治疗恶性胸腹腔积液的研究进展[J]. 现代肿瘤医学, 2019, 0(8): 1441-1444. DOI: 10.3969/j.issn.1672-4992.2019.08.038 |
| |
| 作者姓名： | 刁彦文 董 召 曲秀娟 刘云鹏 曲晶磊 |
| |
| 作者单位： | 中国医科大学附属第一医院肿瘤内科，辽宁 沈阳 110001 |
| |
| 基金项目： | National Natural Science Foundation of China(No.81372547）；国家自然科学基金资助项目（编号:81372547） |
| |
| 摘 要： | 恶性胸腹腔积液是晚期恶性肿瘤最严重并发症之一。对于胸腹腔积液全身化疗效果多不理想，常采用局部治疗。血管内皮生长因子可以促进恶性胸腹腔积液的生成，贝伐单抗是一种抗血管内皮生长因子的单克隆抗体，腔内灌注贝伐单抗在治疗恶性胸腹腔积液方面具有一定的疗效。
|
| 关 键 词： | 贝伐单抗 血管内皮生长因子 腔内灌注 腹水 胸水 |
Research progress of intrapleural or intraperitoneal bevacizumab in treating of malignant pleural and peritoneal effusion |
| |
| Diao Yanwen,Dong Zhao,Qu Xiujuan,Liu Yunpeng,Qu Jinglei. Research progress of intrapleural or intraperitoneal bevacizumab in treating of malignant pleural and peritoneal effusion[J]. Journal of Modern Oncology, 2019, 0(8): 1441-1444. DOI: 10.3969/j.issn.1672-4992.2019.08.038 |
| |
| Authors: | Diao Yanwen Dong Zhao Qu Xiujuan Liu Yunpeng Qu Jinglei |
| |
| Affiliation: | Department of Medical Oncology,the First Hospital of China Medical University,Liaoning Shenyang 110001,China. |
| |
| Abstract: | Malignant pleural and peritoneal effusion is one of the most serious complications of advanced malignancy.At present,the effect of systemic chemotherapy is not ideal for malignant pleural and peritoneal effusion,and local treatment is often used.In recent years,the generation of malignant pleural and peritoneal effusion was found to be directly related to increased secretion of the vascular endothelial growth factor (VEGF).Bevacizumab is a humanized monoclonal antibody against human VEGF.Studies have showed that intrapleural and intraperitoneal bevacizumab was an effective way in the treatment of malignant pleural and peritoneal effusion. |
| |
| Keywords: | bevacizumab VEGF intracavitary perfusion ascites pleural effusion |
|
| 点击此处可从《现代肿瘤医学》浏览原始摘要信息 |
|
点击此处可从《现代肿瘤医学》下载免费的PDF全文 |
